Bosulif (Bosutinib) Patent Expiration, LOE Window & CMS Spending
Bosulif (Bosutinib) by Pfizer: FDA Orange Book core substance LOE 2027-05-23 (last listed 2034-08-28), 2 AB generics, $293.4M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N203341 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2027-05-23 |
| Last Listed Patent or Exclusivity Date | 2034-08-28 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $293.4M |
| 2024 Medicare Part D Spend | $235.3M |
| 2024 Medicaid Spend | $58.0M |
| Reported Wholesale Price Change (CA SB 17) | 15 WAC filings (max 24.3% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.